Media Mentions
Improved Understanding of Genomics Drives Excitement in High-Grade Meningiomas
In OncLive's latest article, they highlight the medical community's increasing interest in how high-grade meningiomas, a common type of brain tumor, might be treated with genomics. Dr. Nader Sanai, at the Ivy Brain Tumor Center, discusses the potential of Phase 0 clinical trials in better testing new treatments for this type of brain cancer.
A New Take on Preclinical Drug Trials for Glioblastoma Treatment
Ivy Center Postdoctoral Fellow Costanza Lo Cascio, PhD, was featured in the latest issue of Oncology Fellows. The article highlights the importance of a pharmacokinetic and pharmacodynamic-guided approach in neuro-oncology preclinical trials to fast-track development of the most promising brain-penetrant drugs for glioblastoma treatment.
Ivy Brain Tumor Center Researcher Wins Grant for Genomic Analysis of Brain Tumors
The Ivy Brain Tumor Center's Pharmacodynamics Core Leader An-Chi Tien has been awarded a one-year, $50,000 grant for work in genetic analysis of meningioma tumors by the American Brain Tumor Association.
“Health Tomorrow” segment: Brain Surgery
The Ivy Center was featured on Health Tomorrow on PBS’ Arizona Horizon to discuss the challenges facing brain tumor patients and the efforts by the Ivy Center to overcome those obstacles. More brain tumor patients are treated at the Ivy Center and Barrow Neurological Institute than in any other facility in the U.S., explained Dr. Nader Sanai, director of the Ivy Center and director of Neurosurgical Oncology at Barrow Neurological Institute.
SonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain Cancer
Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly pediatric brain cancer with a 2% five-year survival rate. To provide therapeutic options for patients and families, SonALAsense is partnering with clinicians at the Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix Children's Hospital, and other sites to conduct a phase 1/2 clinical trial for sonodynamic therapy (SDT). This is the first SDT trial for children.
Team at Ivy Brain Tumor Center works to cure ‘deadliest cancer in humans’
Dr. Nader Sanai spoke with local news station, ABC15 about new developments in brain cancer research and treatment on the fourth anniversary of Senator John McCain's death.
Ivy Brain Tumor Center discusses forms of treatment for rare aggressive brain cancer
Dr. Kelly Braun from the Ivy Brain Tumor Center at Barrow Neurological Institute spoke with Good Morning Arizona reporter Tess Rafols, about new developments and treatments for brain cancer.
Our Bioscience Economy
The Ivy Brain Tumor Center was recognized in a cover story by Greater Phoenix InBusiness as a top-ranked healthcare organization that provides top-notch care, innovation, and research excellence. Learn more -->
Ivy Brain Tumor Center Evaluates AZD1390 in Patients Diagnosed with Recurrent Grade IV Gliomas
A research team at the Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, will evaluate AZD1390 in a Phase 0/1b clinical trial with patients diagnosed with recurrent grade IV gliomas. Onco'Zine covers the full trial and provides more details in this article.
Arizona on the Cutting Edge of Innovative Research Programs
Read about Ivy Brain Tumor Center's innovative research programs and how they are advancing brain cancer treatments. Learn how they are leading the way in Arizona and beyond.